CANCERS BRONCHIQUES A PETITES CELLULES

CANCERS BRONCHIQUES A PETITES CELLULES
ESSAIS TESTANT L’ADDITION D’UN OU DE DEUX MEDICAMENTS A UNE COMBINAISON DE BASE

Référence	Chimiothérapie	stade	n pts	RO	p	SM	p
Edmonson, 1976	1. CPA	tous	118	22%	ND	17,1s	ND
Edmonson, 1976	2. + CCNU	tous	110	43%	ND	11,7s	ND
Hansen, 1978	1. CCNU-CPA-MTX	MD	52	75%	NS	176j	S
Hansen, 1978	2. + VCR	MD	53	78%	NS	230j	S
Maurer, 1980	1. CPA-MTX	ML	41	51%	ND	9,0m	NS
	1. CPA-MTX	ME	40	23%		5,3m
	2. + VCR	ML	47	62%		9,3m
	2. + VCR	ME	33	36%		5,7m
Ettinger, 1982	1. CCNU-CPA	tous	97	28%	ND	21s	NS
Ettinger, 1982	2. + PCZ	tous	95	46%	ND	27s	NS
Jackson, 1984	1. CPA-ADR-VCR	tous	67	64%	S	9,5m	NS
Jackson, 1984	2. + VP16	tous	68	86%	S	10,6m	NS
Lowenbraun, 1984	1. CPA-ADR-VCR	ME	148	72%	NS	42,1s	NS
Lowenbraun, 1984	2. + VP16	ME	145	74%	NS	42,3s	NS
Zhiyi, 1984	1. CPA-ADR-5FU	tous	19			68s	NS
Zhiyi, 1984	2. + PCZ	tous	19			68s	NS
Messeih, 1987	1. CPA-ADR-VCR	tous	49	50%	NS	36s	NS
Messeih, 1987	2. + VP16	tous	43	65%	NS	45s	NS
Jackson, 1988	1. CPA-ADR-VCR	ME	68	46%	S	7,8m	NS
Jackson, 1988	2. + VP16	ME	71	70%	S	9,4m	NS
Niiranen, 1989	1. CPA-VCR	ML	29	46%	NS	12m	NS
Niiranen, 1989	2. + MTX-CCNU	ML	26	56%	NS	16m	NS
Jett, 1990	1. CPA-ADR-VCR	ML	113	83%	NS	12,4m	NS
Jett, 1990	2. + VP16	ML	118	84%	NS	15,1m	NS
Sculier, 1990	1. VP16-VDS	tous	106	55%	S	40s	NS
Sculier, 1990	2. + CDDP	tous	95	74%	S	45s	NS
Nikkanen, 1990	1. CPA-ADR-VCR	ML	41	84%	NS	10m	NS
Nikkanen, 1990	2. + VP16	ML	39	75%	NS	14m	NS
Smith, 1991	1. VCR-ADR-CPA-VP16	tous	48	65%	NS	47s	NS
Smith, 1991	2. + CDDP	tous	47	72%	NS	40s	NS
Miyamoto, 1992	1. CDDP-VP16	tous	45	78%	NS	55s	NS
Miyamoto, 1992	2. + Ifo	tous	47	74%	NS	56s	NS
Gatzemeier, 1994	1. VP16-VCR	ME	173	60%	S	9m	NS
Gatzemeier, 1994	2. + CBDCA	ME	171	80%	S	10m	NS
Loehrer, 1995	1. CDDP-VP16	ME	84	67%	NS	7,3m	S
Loehrer, 1995	2. + Ifo	ME	87	73%	NS	9,1m	S
MRC, 1996	1. VP16-VCR	tous	156	46%	NS	137j	NS
MRC, 1996	2. + CPA-MTX	tous	154	40%	NS	141j	NS
Urban, 1999	1.CPA-ADR-VP16	tous	228	52%	S	266j	NS
Urban, 1999	2. + CDDP	tous	229	72%	S	271j	NS
Hirsch, 2001	1. Carbopl + CDDP + VM26 + VCR puis CPA + épir	Tous	140	71		314 j
		ML	67	78		417 j	S
		ME	68	67		232j	NS
	2. Idem sans CDDP	Tous	149	72		294 j
		ML	74	69		327 j
		ME	60	75		233 j
Pujol, 2001	1. CDDP-VP16	ME	109	61	NS	9,3 m	0,006
Pujol, 2001	2. Idem + CPA-épirubicine	ME	117	76	NS	10,8 m	0,006
Mavroudis, 2001	CDDP 80 +	tous			NS		NS
	I. VP16 80x3 + PAC 175		62	50%		9,5 m
	II. VP16 120 x 3		71	48%		10,5 m
De Marinis, 2005	I. CDDP (70) + gemci (1,25 x2)	ME ou limité de mauvais prono	70	57 %	NS	10 m	NS
De Marinis, 2005	I. CDDP (70) + gemci (1 x2) + VP16 (50 x 3)	ME ou limité de mauvais prono	70	63 %	NS	9,5 m	NS

Références

(1) Edmonson JH, Lagakos SW, Selawry OS, Perlia CP, Bennett JM, Muggia FM et al. Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep 1976; 60(7):925-932.

(2) Hansen HH, Dombernowsky P, Hansen M, Hirsch F. Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination. Ann Intern Med 1978; 89(2):177-181.

(3) Maurer LH, Tulloh M, Weiss RB, Blom J, Leone L, Glidewell O et al. A randomized combined modality trial in small cell carcinoma of the lung: comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactiv whole brain irradiation. Cancer 1980; 45(1):30-39.

(4) Ettinger DS, Lagakos S. Phase III study of CCNU, cyclophosphamide, adriamycin, vincristine, and VP-16 in small-cell carcinoma of the lung. Cancer 1982; 49(8):1544-1554.

(5) Jackson DVJ, Zekan PJ, Caldwell RD, Slatkoff ML, Harding RW, Case LD et al. VP-16-213 in combination chemotherapy with chest irradiation for small- cell lung cancer: a randomized trial of the Piedmont Oncology Association. J Clin Oncol 1984; 2(12):1343-1351.

(6) Lowenbraun S, Birch R, Buchanan R, Krauss S, Durant J, Perez C et al. Combination chemotherapy in small cell lung carcinoma. A randomized study of two intensive regimens. Cancer 1984; 54(11):2344-2350.

(7) Zhiyi Z, Shenzhong W, Xiafang Z. Small cell carcinoma of the lung ; results of a combination chemotherapy and radiation therapy (COF vs COFP randomized analyzed). Int J Radiat Oncol Biol Phys 1984; 10:2139-2143.

(8) Messeih AA, Schweitzer JM, Lipton A, Harvey HA, Simmonds MA, Stryker JA et al. Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer. Cancer Treat Rep 1987; 71(1):61-66.

(9) Jackson DVJ, Case LD, Zekan PJ, Powell BL, Caldwell RD, Bearden JD et al. Improvement of long-term survival in extensive small-cell lung cancer. J Clin Oncol 1988; 6(7):1161-1169.

(10) Niiranen A, Holsti P, Salmo M. Treatment of small cell lung cancer. Two-drug versus four-drug chemotherapy and loco-regional irradiation with or without prophylactic cranial irradiation. Acta Oncol 1989; 28(4):501-505.

(11) Jett JR, Everson L, Therneau TM, Krook JE, Dalton RJ, Marschke RFJ et al. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group. J Clin Oncol 1990; 8(1):33-38.

(12) Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990; 8(9):1556-1562.

(13) Nikkanen V, Liippo K, Ojala A, Jakobsson M, Jarvinen M, Paloheimo S et al. Vincristine, doxorubicin and cyclophosphamide with and without etoposide in limited small cell lung cancer. Acta Oncol 1990; 29(4):421-424.

(14) Smith AP, Anderson G, Chappell G, Bowen DR. Does the substitution of cisplatin in a standard four drug regimen improve survival in small cell carcinoma of the lung? A comparison of two chemotherapy regimens. Thorax 1991; 46(3):172-174.

(15) Miyamoto H, Nakabayashi T, Isobe H, Akita H, Kawakami Y, Arimoto T et al. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology 1992; 49(6):431-435.

(16) Gatzemeier U, Pawel JV, Laumen R, Hossfeld DK, Neuhauss R. Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: a prospective randomized phase III trial. Semin Oncol 1994; 21(3 Suppl 6):31-35.

(17) Loehrer PJS, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A et al. Cisplatin plus etoposide with and without ifosfamide in extensive small- cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995; 13(10):2594-2599.

(18) Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party [published erratum appears in Br J Cancer 1996 Sep;74(6):997]. Br J Cancer 1996; 73(3):406-413.

(19) Urban T, Chastang C, Lebas FX, Duhamel JP, Adam G, Darse J et al. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. "Petites Cellules" Group. Cancer 1999; 86(11):2238-2245.

(20) Hirsch FR, Osterlind K, Jeppesen N, Dombernowsky P, Ingeberg S, Sorensen PG et al. Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients. Ann Oncol 2001; 12(5):647-653.

(21) Pujol JL, Daures JP, Riviere A, Quoix E, Westeel V, Quantin X et al. Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study. J Natl Cancer Inst 2001; 93(4):300-308.

(22) Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001; 12(4):463-470.

(23) De Marinis F, Nelli F, Lombardo M, Ferrau F, Barbera S, Bertetto O et al. A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma. Cancer 2005; 103(4):772-779.